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Rats	i.p.	injected	once	with	10	mg/kg	kainic	acid	exhibited	clear	seizure	behavior	(“wet­dog	
shakes,”	rearing	on	the	hindlimbs,	and	bilateral	clonus).	Pretreatment	with	L­arginine	(L­Arg	
twice	 a	 day	 for	 5	 days)	 significantly	 decreased	 these	manifestations.	The	medium	dose	 of	 
L­Arg	(40	mg/kg)	was	found	to	be	close	to	optimum;	10	and	160	mg/kg	L­Arg	provided	much	
smaller	positive	effects.	 In	KA­treated	rats,	a	much	higher	density	of	GFAP­positive	astro­
cytes	was	found	in	the	hilus		of	the	dorsal	hippocampus,	while	40	mg/kg	L­Arg+KA­treated	
rats	demonstrated	noticeably	weaker	GFAP	overexpression.	The	results	of	Western	blotting	
analysis	were	fully	comparable	with	those	obtained	in	the	immunostaining	experiments.	
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INTRODUCTION 
L­Arginine	(L­Arg)	first	isolated	in	1886	is	one	of	the	
20	 most	 common	 natural	 amino	 acids.	 In	 mammals,	
arginine	is	classified	as	a	semiessential	or	conditionally	
essential	amino	acid	(depending	on	the	developmental	
stage	and	health	status	of	the	individual)	[1].	Preterm	
infants	 are	 unable	 to	 synthesize	 arginine	 internally,	
making	 this	 amino	 acid	 nutritionally	 essential	 for	
them	 [2].	 There	 are	 some	 conditions	 that	 cause	
increased	requires	of	the	organism	for	the	synthesis	of	
L­arginine,	including	surgical	or	other	trauma,	sepsis,	
and	 burns.	 It	 should	 be	 taken	 into	 consideration	 that	
L­Arg	is	the	substrate	for	nitric	oxide	(NO)	synthesis.
Kainic	acid	(KA)	is	a	natural	organic	acid	existing	
in	some	seaweed.	It	is	a	specific	agonist	for	the	kainate	
receptors,	a	subtype	of	ionotropic	glutamate	receptors	
for	 	 which	 KA	 can	 imitate	 the	 effect	 of	 glutamate.	
Kainic	acid	is	a	potent	stimulant	of	the	CNS	used	for	
the	 induction	 of	 seizures	 in	 experimental	 animals;	
in	 particular,	KA	 allows	 experimenters	 to	 build	 up	 a	
rat	 model	 of	 epilepsy.	 As	 was	 demonstrated	 earlier,	
NO	may	 alleviate	 seizures	 and,	 thus,	 may	 be	 a	 kind	
of	 endogenous	 antiepileptics	 [3].	 However,	 the	
mechanism	of	NO	action	 in	 this	 respect	 still	 remains	
unclear.	
It	 has	 been	 reported	 that	 reactive	 proliferation	
of	 astrocytes	 occurs	 during	 the	 process	 of	
neurodegeneration	 or	 brain	 injury,	 and	 this	 is	
accompanied	 by	 intensification	 of	 the	 synthesis	 of	
glial	 fibrillary	 acidic	 protein	 (GFAP),	 a	 cell­specific	
marker	 for	 reactive	astrocytes	 [4­6].	 Increased	GFAP	
immunoreactivity	 [7­8]	 and	 the	 respective	 mRNA	
levels	were	 found	 in	 seizure­manifesting	 rats	 [9­11].	
The	question	whether	L­Arg,	an	important	component	
of	the	NO	system,	exerts	any	effect	on	the	expression	
of	 GFAP	 has	 not	 yet	 been	 clarified.	 This	 is	 why	 we	
investigated	 the	effects	of	L­Arg	on	seizure	behavior	
and	expression	of	GFAP	in	KA­treated	rats.	
METHODS
Animals and Treatments. Male	 Wistar	 rats (mean	
body	mass	230	±	20	g)	were	obtained	from	the	Experi­
mental	Animal	Center	of	the	Dalian	Medical	Universi­
ty	(China).	Sixty	animals	were	randomly	selected	and	
divided	 into	 six	 groups.	 Rats	 of	 three	 L­Arg­treated	
groups	were	i.p.	 injected	with	10,	40,	and	160	mg/kg	 
L­Arg	 twice	 a	 day	 for	 5	 days,	 respectively.	Animals	
the	KA­treated		group	were	i.p.	injected	with	10	mg/kg	
KA	once	on	the	6th	day	after	L­Arg	pretreatment.	The	
normal	 control	 and	 negative	 control	 groups	were	 in­
jected	with	physiological	saline	(2	ml/kg)	at	the	same	
time	as	the	groups	mentioned	above.	
Behavioral Observations.	 All	 rats	 injected	 with	 
10	 mg/kg	 KA	 demonstrated	 brisk	 rotational	
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movements	 of	 the	 head	 and	 trunk	 called	 “wet	 dog	
shakes”	(WDSs).	The	onset	of	seizures	and	the	degree	
of	 their	 severity	 were	 estimated	 using	 a	 point	 scale	
proposed	by	Racine	[12]:	1,	chewing;	2,	head	nodding;	
3,	unilateral	forelimb	clonus;	4,	rearing	with	bilateral	
forelimb	clonus;	and	5,	rearing	with	bilateral	forelimb	
clonus	 and	 falling	back.	Behavior	 of	KA­treated	 rats	
was	monitored	for	3	h	after	KA	administration.
Immunohistostaining.	 After	 observing	 seizure	
behavior,	 the	 rats	 were	 i.p.	 anesthetized	 with	
pentobarbitone	 and	 perfused	 transcardially	 with	 4%	
paraformaldehyde.	 The	 brains	 were	 removed	 and	
immersed	 in	 20%	 sucrose	 diluted	 in	 0.1	M	 phosphate­
buffered	 saline	 (PBS,	 pH	7.4).	Brain	 samples	were	 cut	
into	 50­mm­thick	 slices.	 The	 latter	 were	 first	 rinsed	 in	
PBS	 for	 10	min	 and	 then	 consequently	 incubated	with	
bovine	 serum	 albumin	 (BSA)	 for	 30	 min,	 incubated	
with	the	primary	GFAP	antibody	(1:3,000)	overnight	at	
4°C,	rinsed	in	PBS	for	10	min,	and	then	incubated	with	
biotinylated	 goat	 anti­rabbit	 serum	 (1:500)	 and	 avidin­
biotin	complex	(ABC)	for	3	h.	Diaminobenzidine	(DAB)	
provided	visualization	of	staining.	Control	sections	were	
incubated	with	PBS	instead	of	the	primary	antibody.
Pathological Image Analysis.	 A	 HPIAS	 series	
colorful	 pathology	 photograph	 system	 was	 used	 to	
analyze	 GFAP­immunopositive	 (ip)	 cells.	 The	 test­
squares	 in	 the	 screen	 of	 the	 microscope	 used	 were	
194258	 mm2,	 and	 the	 number	 and	 average	 optical	
density	of	GFAP­ip	cells	were	measured	within	these	
squares.
Western Blotting Analysis.	 Hippocampal	 samples	
were	 removed,	 weighed,	 homogenized	 in	 Tris	 buffer	
saline	 (TBS,	 pH	 7.5)	 for	 15	 sec,	 and	 then	 vigorously	
vortexed	for	10	sec.	Parts	of	the	homogenized	samples	
(100	 ml)	 were	 heated	 at	 100°C	 for	 5	 min	 and	 then	
centrifuged	 at	 13,000	 rpm	 for	 5	 min.	 Ten	 microliters	
of	 the	 supernatant	 were	 used	 for	 quantifying	 protein	
according	 to	 the	Smith’s	method	 [11].	Another	100	ml 
of	homogenized	samples	were	added	to	an	equal	volume	
of	the	sample	loading	buffer,	heated	at		100°C	for	5	min,	
and	 then	 centrifuged	 at	 13,000	 rpm	 for	 5	 min.	After	
these	 procedures,	 electrophoresis,	 transferring,	 and	
identifying	 were	 carried	 out.	 Markers	 were	 cut	 away	
from	the	membrane,	stained,	destained,	and	dried,	while	
the	other	part	of	the	membrane	was	washed	twice	with	
TBS	for	10	min	and	then	immobilized	by	1%	BSA	for	
1	h.	Next	operations	were	incubation	with	the	primary	
antibody	 against	 GFAP	 (1:1,500)	 and	 subsequent	
incubation	 with	 the	 secondary	 antibody	 and	ABC	 for	 
1	h.	Finally,	photographs	were	taken	and	analyzed.	
Statistics.	 The	 numerical	 results	 are	 shown	 as	
means	±	s.d.,	and	the	one­way	ANOVA	test	was	used	
to	evaluate	the	statistical	significance	(P <	0.05).
RESULTS
Behavior. The	 KA­treated	 rats	 in	 the	 model	 group	
exhibited	clear	time­dependent	seizure	behavior.	Five	
minutes	after	KA	injection,	staring	and	WDSs	occurred	
during	30	min	to	1	h.	Spontaneous	stereotyped	seizure	
behavior	 happened	 within	 a	 1­	 to	 3­h­long	 interval;	
this	 was	 characterized	 by	 rearing	 on	 the	 hindlimbs	
with	 bilateral	 clonus,	 until	 the	 balance	 was	 lost.	 In	
comparison	 with	 the	 control	 group,	 animals	 of	 the	
160	mg	L­Arg		+	10	mg/kg	KA­injected	group	showed	
much	 longer	 WDS	 latencies	 with	 no	 significant	
differences	 in	 the	 rearing	 latency	 and	 seizure	 scores.	
However,	40	mg/kg	L­Arg	+	KA­treated	 rats	 showed	
much	longer	WDS	latencies	and	rearing	latencies	with	
lower	 seizure	 scores,	 while	 10	 mg/kg	 L­Arg	 +	 KA­
treated	 group	 showed	 no	 significant	 changes.	 These	
results	suggested	that	10	mg/kg	L­Arg	could	alleviate	
the	 normal	 condition	 only	 mildly,	 while	 	 40	 mg/kg	
L­Arg	alleviated	the	condition	obviously.	This	proved	
that	the	effect	of	L­Arg	on	abnormal	behavior	induced	
by	KA	is	dose­dependent,	and	 that	 the	optimum	dose	
of	L­Arg	is	about	40	mg/kg,	as	illustrated	in	Table	1.
Table 1.  Effects of Different Doses of L-Arginine (L-Arg) on Kainic Acid (KA)-Induced Seizure Behavior in Rats
Т а б л и ц я. 1. Вплив L-аргініну на прояви судом, викликаних дією каїнової кислоти
Animal	groups injected	with	
different	agents
WDS	latency,	min Rearing	latency,	min Score	of	seizures
2	ml/kg	PS+10	mg/kg	KA	 26.44	±	1.21 77	±	2.17 23.19	±	0.83
10 mg/kg	L­Arg	+10 mg/kg	KA 25.12 ± 1.06 76 ± 2.20 22.17±0.79
40 mg/kg	L­Arg+	10 mg/kg	KA 33.75	±	1.29** 90	±	3.15** 16.25	±	0.77**
160	mg/kg	L­Arg	+	10	mg/kg	KA 34.62	±	1.73** 89 ±	4.55 21.35	±	0.63
Footnotes.	**Significant	difference	from	physiological	saline	(PS)	+	KA­injected		group	with	P < 0.01	(n	=	10).	WDS)	“Wet	dog	shakes”	
(brist	rotational	movements	of	the	head	and	trunk).		
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Immunohistostaining Analysis. In	 comparison	
with	 the	 control	 group,	 the	 number	 and	 the	 density	
of	 GFAP­ip	 astrocytes	 in	 KA­treated	 rats	 were	
significantly	 greater	 in	 the	 hilus	 of	 the	 dorsal	
hippocampus.	A	bandlike	distribution	of	astrocytes	was	
clearly	 observed,	 the	 general	 intensity	 of	 staining	 of	
the	GFAP­ip	units	was	markedly	greater,	and		strongly	
labeled		immunoreactive	elements	were	almost	entirely	
located in the  hilus	and	adjacent	regions.	A	majority	
of	the	GFAP­ip	cells	appeared	larger	and	were	stained	
more	heavily,	with	positive	processes	appearing	more	
clearly.	However,	 40	mg/kg	L­Arg	+	KA­treated	 rats	
demonstrated	 noticeably	 weaker	 overexpression	 of	
GFAP­ip	 astrocytes	 mentioned	 	 above;	 there	 was	 no	
statistically	significant	difference	from	the	expression	
in	the	control	groups	(Fig.	1	and	Table	2).	
TABLE 2. Numbers of GFAP-ip Astrocytes and Pathological Image Analysis in the Hilus of the Rat Dorsal Hippocampus 
Т а б л и ц я 2. Кількість GFAP-імунопозитивних астроцитів та прояви патологічних змін у хілусі дорсального гіпокампа щурів 
Animal	groups	injected	
with	different	agents	 N S,	μm
2 D ID
2	ml/kg	PS 10.08 ± 0.93 402.74 ± 10.92 0.71 ± 0.01 375.74 ± 6.02
40	mg/kg	L­Arg 10.17 ± 0.96 400.00 ± 16.81 0.70 ± 0.01 374.77 ± 7.04
2	ml/kg	PS	+ 
+	10	mg/kg	KA 14.13 ± 0.68
** 715.42 ± 17.01** 0.90 ± 0.03* 610.29 ± 21.00**
40	mg/kg	L­Arg	+	 
+	10	mg/kg	KA 10.38 ± 0.56
## 388.60 ± 12.68## 0.69 ± 0.01## 355.06 ± 14.32##
Footnotes.	N)	Number	of	positive	cells,	S)	surface	area	of	the	positive	bodies,	D)	average	optical	density,	and	ID)	integral	optical	density	per	
one	sight	region	(194,258	mm2, n	=	15­20	sections).	* Significant	difference	from	the	control	PS­injected		group	at	P <	0.05.  ** Significant	
difference	from	the	control	PS­injected	group	at	P < 0.01.	## Significant	difference	from	the	PS	+	KA­injected	group	at	P < 0.01.	Other 
designations are the same as in Table	1.
F i g. 1.	Effect	of	40	mg/kg	L­arginine	 (L­Arg)	on	
expression	 of	 GFAP­ip	 astrocytes	 in	 the	 rat	 dorsal	
hippocampus.	 A­D)	 Hippocampal	 slices	 obtained	
from	 a	 control	 animal	 injected	 with	 physiological	
saline	 (2	ml/kg,	A),	 a	 10	mg/kg	 kainic	 acid	 (KA)­
treated	rat	(B),	an	L­Arg­injected	animal	(C),	and	a	
KA	+	L­Arg­treated	animal.	m	and	g)	Molecular	and	
granular	 layers	 	 of	 the	 dentate	 gyrus,	 respectively;	 
h)	 hilus	 of	 the	 dentate	 gyrus,	 and	 p)	 stratum 
pyramidale of the CA3.
Р и с. 1.	Вплив	40	мг/кг	L­аргініну	на	експресію	
гліального	фібрилярного	кислого	протеїну	(GFAP)	
в	астроцитах	дорсального	гіпокампа	щура.
A
C
B
D
NEUROPHYSIOLOGY	/	НЕЙРОФИЗИОЛОГИЯ.—2013.—T.	45,	№	128
Yi.	SUN,	Sh.	YIN,	Sh.	LI	et	al.
Western Blotting Analysis.	The	molecular	mass	of	
GFAP	 is	 about	 50	 kDa.	 Three	 hours	 after	 KA	 injec­
tion,	GFAP	expression	was	obviously	more	intense	in	
the	PS­treated	+	KA­injected		group.	At	the	same	time,	
such	 expression	 in	 the	 	 40	 mg/kg	 L­Arg	 +	 KA­rats	
was	noticeably	weaker	and	showed	no	significant	dif­
ference	vs that	 in	 the	PS­injected	 group	 (Figs.	 2	 and	
3).	These	results	are	 fully	comparable	with	 those	ob­
tained	in	the	immunohistostaining	experiments.
DISCUSSION
Nitric	 oxide	 has	 been	 implicated	 in	 mediation	 of	
neuronal	 excitotoxic	 injury	 [14­15].	 L­arginine	 (the	
substrate	 for	 NO	 synthesis),	 regarded	 as	 the	 main	
endogenous	 source	 for	 NO	 production,	 was	 used	 in	
our	experiments	to	study	the	role	of	NO	in	generation	
of	seizures	in	KA­treated	rats.	It	was	reported	earlier	
that	 pretreatment	 with	 L­Arg	 tends	 to	 potentiate	 the	
effects	 of	 quinolinic	 acid	 (QA)	 and	 induces	 clonic	
and	 tonic	 convulsions	 in	 mice	 [16].	 Simultaneously,	
the	effects	of	L­Arg	on	seizure	activity	elicited	by	KA	
are	 dose­dependent	 and	 contribute	 to	 the	 genesis	 of	
seizure	 activity	 [17].	At	 the	 same	 time,	 it	was	 found	
that	L­Arg	did	not	affect	kindling	or	 seizure	severity	
[18].	 Other	 studies	 showed	 that	 NO	might	 act	 as	 an	
endogenous	 anticonvulsant	 in	 mice	 [19­20],	 and	 the	
anticonvulsant	L­Arg	alone	significantly	increases	the	
NO	concentration	 and	NOS	activity	 in	 specific	 brain	
regions	 responsible	 for	 suppression	 of	 convulsions	
[21­22].	 Previous	 studies,	 however,	 indicated	 that	
KA­induced	seizures	appeared	later	in	rats	pretreated	
with	a	single	large	dose	of	L­Arg	[18­21].	
Due	 to	 all	 the	 above­mentioned	 controversies,	 we	
investigated	the	effects	of	chronic	treatment	with	small	
doses	 of	 L­Arg	 on	KA­induced	 seizures.	 The	 results	
showed	that	pretreatment	with	40	mg/kg	L­Arg	clearly	
alleviated	 KA­induced	 seizures,	 while	 pretreatment	
with	 the	 lower	 (10	 mg/kg)	 or	 greater	 (160	 mg/kg)	
doses	of	L­Arg	demonstrated	 less	 significant	 effects.	
Thus,	 the	 dose	 dependence	 is	 probably	 	 U­like.	 We	
also	 observed	 that	 chronic	 treatment	 with	 moderate	
doses	 of	 L­Arg	 (40	 mg/kg)	 exhibited	 anticonvulsant	
effects.	
The	 results	 presented	 here	 indicate	 that	 chronic	
treatment	 with	 moderate	 doses	 of	 L­Arg	 (40	 mg/kg)	
provide	 an	 anticonvulsant	 action,	 but	 the	mechanism	
of	 such	 effect	 still	 remains	 unclear.	 Astrocytes	
perform	a	variety	of	 functions	 in	 the	 adult	CNS	 [23­
24].	Reactive	 gliosis	 is	 a	 response	 of	 astrocytes	 to	 a	
variety	of	insults	that	is	characterized	by	hypertrophy	
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F i g. 2.		Expression	of	GFAP	in	the	rat	hippocampus	demonstrated	
using	 Western	 blot	 analysis.	 A)	 Control	 (physiological	 saline­
injected)	 group,	 B)	KA­treated	 rats,	 C)	 40	mg/kg	 L­Arg­injected	
animals,	and	D)	KA	+	40	mg/kg	L­Arg­treated	group.	S)	Standard	
molecular	 mass	 (kDa)	 of	 the	 markers,	 from	 top	 to	 bottom,	 97.4	
(phosphorylase),	 66.2	 (bovine	 serum	 albumin),	 55.0	 (glutamate	
dehydrogenase),	42.7	(ovalbumin),	and	40.0	(aldolase).	Each	 lane	
showes	 an	 identical	major	band	 stained	 strongly	 at	 about	50	kDa	
position.
Р и с. 2. Експресія GFAP	у	гіпокампі	щурів:	результати	Вестерн­
блотингу.
F i g. 3.	 	 Results	 of	 scanning	 of	 hippocampal	 GFAP	 expression	 
(n	=	6).	L­Arg)	L­arginine,	KA)	kainac	acid.	*	Significant	difference	
from	 the	 control	 physiological	 saline­injected	 group	 (PS)	 at	 
P	 <	 0.05.	 +	Significant	 difference	 from	PS	+	KA­treated	 group	 at	 
P	<	0.05.	Vertical	scale)	Relative	optical	density.
Р и с. 3.	Результати	сканування	при	дослідженні	експресії	GFAP 
у	гіпокампі	щурів.
Actin
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of	the	cell	bodies	and	processes	and	an	increase	in	the	
expression	of	GFAP	[25­26]. Previous	studies	revealed	
that	a	single	convulsive	KA­induced		seizure	episode	
strongly	 intensifies	GFAP	expression	 in	astrocytes	 in	
the	 hippocampal	 formation.	 Bennett	 et	 al.	 reported	
that GFAP	 immunopositivity	 was	 enhanced	 in	 the	
hippocampus	and	correlative	brain	areas	3	h	after	KA	
injection,	 but	 the	 specific	 distribution	 and	 alteration	
were	not	described	 [27,	28].	Our	 results	 showed	 that	
GFAP	 expression	 after	 L­Arg	 pretreatment	 reduced	
KA­challenged	 seizure	behavior.	Furhtermore,	L­Arg	
pretreatment	 with	 the	 dosage	 of	 40	 mg/kg	 inhibited	
hyperplasia	 and	 hypertrophy	 of	 the	 astrocytes	 and	
bandlike	 distribution	 of	 these	 glial	 cells	 and	 also	
alleviated	 the	 abnormal	 overexpression	 of	 GFAP	
induced	by	KA.	
Thus,	 our	 study	 suggests	 that	 the	 effect	 of	NO	 on	 
KA­induced	 seizures	 is	 dose­dependent,	 and	 that	 the	
L­Arg	 dose	 of	 40	 mg/kg	 seems	 to	 be	 optimum	 for	
correction	 of	 KA­induced	 abnormal	 behavior.	 The	
effect	may	 be	 related	 to	 regulation	 of	 the	 expression	
of	 GFAP	 and	 to	 a	 protecting	 action	 with	 respect	 to	
astrocytes.	In	future,	we	will	try	to	block	NO	expression	
and	 to	 observe	 behavioral	 changes	 and	 changes	 in	
astrocytes	in	KA­treated	animals.	It	is	necessary	to	be	
sure	 that	NO	 is	 the	key	point	 for	 curing	KA­induced	
seizures	 and	 to	 make	 clear	 the	 possible	 mechanism	
of	the	action	of	the	optimum	L­Arg	dose	(40	mg/kg),	
which	most	effectively	reduced	abnormal	behavior	in	
KA­treated	rats.
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Р	е	з	ю	м	е
Поведінка	 щурів,	 яким	 внутрішньоочеревинно	 ін’єкували	
10	мг/кг	каїнової	кислоти	(КК),	характеризувалася	вираже­
ними	 проявами	 судом,	 „струшуваннями	 мокрого	 собаки”,	
вставанням	 на	 задні	 кінцівки	 та	 білатеральним	 клонусом.	
Попередні	введення	L­аргініну	(L­Aрг)	двічі	на	день	протя­
гом	п’яти	днів	забезпечували	 істотне	зменшення	 інтенсив­
ності	таких	проявів.	Було	виявлено,	що	доза	L­Aрг	40	мг/кг	
є	близькою	до	оптимальної;	дози	10	та	160	мг/кг	справляли	
менш	виражену	позитивну	дію.	У	щурів,	яким	уводили	КК,	
у	хілусі	дорсального	гіпокампа	спостерігалася	більш	висо­
ка	щільність	астроцитів,	 імунопозитивних	 	щодо	гліально­
го	фібрилярного	кислого	білка	 (GFAР),	у	 той	час	як	у	щу­
рів,	котрим	уводили	КК	сумісно	із	40	мг/кг	L­Арг,	експресія	
GFAP	була	виражена	в	помітно	меншій	мірі.	Результати	до­
сліджень	з	використанням	Вестерн­блотингу	були	повністю	
співставними	з	даними,	отриманими	в	експериментах	з	іму­
ногістологічним	міченням.	
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